文献速递冠心病血脂与心血管预防

肠溶阿司匹林与普通阿司匹林在心血管病患者中的疗效与安全性

Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

本分析基于ADAPTABLE随机临床试验的事后二次分析,纳入10 678例自报基线阿司匹林剂型的动脉粥样硬化性心血管病患者,其中7366例(69.0%)服用肠溶阿司匹林、3312例(31.0%)服用普通阿司匹林。中位随访26.2个月,肠溶与普通阿司匹林在主要疗效终点(心肌梗死、卒中或全因死亡)和主要安全终点(大出血)上均无显著差异,且剂量与剂型间无显著交互作用。

要点

  • 肠溶与普通阿司匹林的疗效复合终点无显著差异(AHR 0.94;95%CI 0.80-1.09;P=.40)。
  • 大出血风险两者亦无显著差异(AHR 0.82;95%CI 0.49-1.37;P=.46),但不能排除肠溶制剂减少出血的可能。
  • 剂型与阿司匹林剂量对疗效和安全终点均无显著交互作用。

核心结论

  • 在ADAPTABLE事后二次分析中,肠溶阿司匹林与普通阿司匹林相比,未显著升高心肌梗死、卒中或死亡风险,也未显著降低出血风险,但不能排除肠溶制剂减少出血的可能。

研究设计与样本

  • ADAPTABLE(NCT02697916)的事后二次分析,该实用型研究共纳入15 076例动脉粥样硬化性心血管病患者,随机接受每日高剂量325 mg或低剂量81 mg阿司匹林。
  • 本次分析按基线自报阿司匹林剂型重新分组,共10 678例有剂型数据,中位(IQR)随访26.2(19.8-35.4)个月。
  • 采用未调整和多变量Cox比例风险模型比较累积发生率,分析基于意向治疗人群。

主要发现

  • 肠溶阿司匹林组7366例(69.0%),普通阿司匹林组3312例(31.0%);中位(IQR)年龄68.0(61.3-73.7)岁,男性7285例(68.2%)。
  • 主要疗效终点(心肌梗死、卒中或全因死亡复合终点)无显著差异:AHR 0.94;95%CI 0.80-1.09;P=.40。
  • 主要安全终点(大出血事件)无显著差异:AHR 0.82;95%CI 0.49-1.37;P=.46。
  • 剂型内剂量比较:肠溶阿司匹林疗效AHR 1.13(95%CI 0.88-1.45)、普通阿司匹林AHR 0.99(95%CI 0.83-1.18),交互P=.41。
  • 剂型内剂量比较:肠溶阿司匹林安全AHR 2.37(95%CI 1.02-5.50)、普通阿司匹林AHR 0.89(95%CI 0.49-1.64),交互P=.07。

临床怎么用

  • 对于动脉粥样硬化性心血管病二级预防患者,选择肠溶或普通阿司匹林在疗效与出血风险上未见显著差异,可结合患者耐受性和偏好个体化选择。
  • 不应以肠溶剂型作为降低出血风险的确定依据,出血高风险患者仍需评估并管理出血危险因素。

局限性

  • 本研究为事后二次分析,剂型分组基于患者自报而非随机分配,可能存在选择偏倚和未测量混杂。
  • 出血事件数较少,安全终点置信区间较宽,不能排除肠溶阿司匹林减少出血的可能。
  • 结论需更多研究确认肠溶或新型阿司匹林制剂能否改善该人群结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulations. OBJECTIVE: To assess whether receipt of enteric-coated vs uncoated aspirin is associated with effectiveness or safety outcomes. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc secondary analysis of ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness), a pragmatic study of 15 076 patients with atherosclerotic cardiovascular disease having data in the National Patient-Centered Clinical Research Network. Patients were enrolled from April 19, 2016, through June 30, 2020, and randomly assigned to receive high (325 mg) vs low (81 mg) doses of daily aspirin. The present analysis assessed the effectiveness and safety of enteric-coated vs uncoated aspirin among those participants who reported aspirin formulation at baseline. Data were analyzed from November 11, 2019, to July 3, 2023. INTERVENTION: ADAPTABLE participants were regrouped according to aspirin formulation self-reported at baseline, with a median (IQR) follow-up of 26.2 (19.8-35.4) months. MAIN OUTCOMES AND MEASURES: The primary effectiveness end point was the cumulative incidence of the composite of myocardial infarction, stroke, or death from any cause, and the primary safety end point was major bleeding events (hospitalization for a bleeding event with use of a blood product or intracranial hemorrhage). Cumulative incidence at median follow-up for primary effectiveness and primary safety end points was compared between participants taking enteric-coated or uncoated aspirin using unadjusted and multivariable Cox proportional hazards models. All analyses were conducted for the intention-to-treat population. RESULTS: Baseline aspirin formulation used in ADAPTABLE was self-reported for 10 678 participants (median [IQR] age, 68.0 [61.3-73.7] years; 7285 men [68.2%]), of whom 7366 (69.0%) took enteric-coated aspirin and 3312 (31.0%) took uncoated aspirin. No significant difference in effectiveness (adjusted hazard ratio [AHR], 0.94; 95% CI, 0.80-1.09; P = .40) or safety (AHR, 0.82; 95% CI, 0.49-1.37; P = .46) outcomes between the enteric-coated aspirin and uncoated aspirin cohorts was found. Within enteric-coated aspirin and uncoated aspirin, aspirin dose had no association with effectiveness (enteric-coated aspirin AHR, 1.13; 95% CI, 0.88-1.45 and uncoated aspirin AHR, 0.99; 95% CI, 0.83-1.18; interaction P = .41) or safety (enteric-coated aspirin AHR, 2.37; 95% CI, 1.02-5.50 and uncoated aspirin AHR, 0.89; 95% CI, 0.49-1.64; interaction P = .07). CONCLUSIONS AND RELEVANCE: In this post hoc secondary analysis of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of myocardial infarction, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02697916.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Sleem A, Effron MB, Stebbins A, et al. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37792369. doi:10.1001/jamacardio.2023.3364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。